


Accelerating Innovations into CarE – Validate Program (AICE-Validate)



Cordyva: A Potent and Safe Treatment of Long COVID

PROJECT FAST FACTS

RECIPIENT: SinoVeda Canada Inc.

AWARD: \$300,000

AWARD DATE: March 1, 2024

PROJECT DURATION: 24 months

THE PROBLEM

Long COVID has emerged as a debilitating outcome of the COVID-19 infection with no cure or remediation yet available. Long COVID patients report a diverse spectrum of symptoms, with some reporting over 200 different physical and mental ailments, including fatigue, cognitive disruptions, and sensory anomalies. More concerning is the evidence suggesting potential multi-organ damage, even in patients initially deemed low risk. In Canada, 15 percent of individuals diagnosed with COVID-19, equivalent to 1.4 million people, have Post COVID condition (PCC) with half experiencing symptoms lasting over a year. Nearly a quarter reported severe disruption to their daily activities, while three quarters reported interruptions in work or studies, averaging an absenteeism of 20 days. This condition extends beyond health, highlighting significant economic and societal challenges and necessitating global collaboration to reach definitive diagnosis criteria and treatments.

THE SOLUTION

Sinoveda's Cordyva is a combination therapy using Cordyceps, a key component in traditional Chinese Medicine to address the complex nature of COVID-19 and Long COVID. Cordyva is composed of three compounds, chosen based on their impact on pathways involved in viral replication, inflammation, immune response, coagulation, and fibrosis. This therapy represents a significant advancement from computational research to market availability.

PROJECT OBJECTIVES

1. *Preclinical studies are proposed to measure the effects of these compounds both individually and in combination, aiming to evaluate their individual activities and determine their combined synergistic effects.; and*
2. *Conduct a formal clinical trial to verify the efficacy and safety of Cordyva in post-COVID condition patients.*

ABOUT THE AICE-VALIDATE PROGRAM

AICE-Validate is an opportunity for Alberta's health-tech innovators to accelerate commercialization of digital and data-enabled health technologies through the early validation phase. If you'd like to learn more, please check out [AICE Validate on the Alberta Innovates website](#).

Learn how

albertainnovates.ca